GlassScriptPhysician profile
Prasad Srinivasan
NPI 1740253517
$13,550.98
in general payments reported to CMS, 2019-2025
33 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,949 · 2020: $2,124 · 2021: $1,683 · 2022: $2,261 · 2023: $2,907 · 2024: $2,245 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,435 · Education: $99.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,435.03 |
| Education | $99.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,489.99 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,916.78 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $1,809.40 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,186.60 | 2019-2025 | |
| Medtronic USA, INC. | $1,120.00 | 2020 | |
| Biocryst US Sales Co., LLC | $868.40 | 2022-2024 | Orladeyo |
| Optinose US, INC. | $478.92 | 2019-2024 | |
| Amgen INC. | $464.13 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $455.63 | 2019-2024 | |
| Abbvie INC. | $354.87 | 2022-2025 | Rinvoq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.58 | 2019-2022 | |
| Alk-Abello, INC | $321.59 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Genentech USA, INC. | $275.13 | 2019-2025 | Xolair |
| Csl Behring | $235.38 | 2020-2025 | Haegarda |
| Pfizer INC. | $192.60 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $190.71 | 2021-2025 | Takhzyro, Cuvitru, Hyqvia |
| Aimmune Therapeutics, INC. | $105.93 | 2021-2022 | |
| Leo Pharma INC. | $105.76 | 2022-2024 | Adbry |
| Phadia US INC. | $99.76 | 2019-2024 | Immunocap |
| Blueprint Medicines Corporation | $95.81 | 2022-2023 | Ayvakit |
| Pharming Healthcare, INC. | $78.17 | 2019-2022 | |
| Greer Laboratories, INC. | $62.55 | 2019-2020 | |
| Uswm, LLC | $46.05 | 2021 | |
| Seqirus USA INC | $45.02 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Hikma Pharmaceuticals USA | $34.78 | 2022-2024 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $31.32 | 2020 | |
| Inspire Medical Systems, INC. | $30.00 | 2024 | Inspire |
| Ars Pharmaceuticals Operations, INC. | $25.23 | 2025 | Neffy |
| Octapharma USA, INC. | $22.42 | 2019 | |
| Merck Sharp & Dohme LLC | $21.02 | 2023 | |
| Incyte Corporation | $19.05 | 2022 | |
| Kaleo, INC. | $17.88 | 2022 | |
| Eisai INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasad Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.